Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 356

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 356
---
 of 250 shares or more to one.

Accordingly, and
as described in the Letter, unless the Company timely requested a hearing before a Hearings Panel (the “Panel”), the Company’s
securities would be subject to suspension/delisting. Accordingly, the Company requested a hearing before the Panel. The hearing request
will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted
by the Panel following the hearing.

On September 19, 2024, the Company announced a ratio change on its
ADSs from one (1) ADS representing four hundred (400) ordinary shares, to the new ratio of one (1) ADS representing ten thousand (10,000)
ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be October 4, 2024.

| F-19 |

<div align='center'>BIODEXA PHARMACEUTICALS PLC

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</div>

|                                                                                                             | Page |
| Report of Independent Registered Public Accounting Firm (Mazars LLP, London, United Kingdom, PCAOB ID 1401) | F-21 |
| Consolidated statements of comprehensive income for the years ended 31 December 2023, 2022 and 2021         | F-23 |
| Consolidated statements of financial position at 31 December 2023, 2022 and 2021                            | F-24 |
| Consolidated statements of cash flows for the years ended 31 December 2023, 2022 and 2021                   | F-26 |
| Consolidated statements of changes in equity for the years ended 31 December 2023, 2022 and 2021            | F-28 |
| Notes forming part of the consolidated financial statements                                                 | F-31 |

| F-20 |

<div align='center'>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

The Board of Directors and Shareholders of Biodexa Pharmaceuticals
plc (formerly known as Midatech Pharma plc)

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated
statements of financial position of Biodexa Pharmaceuticals plc (formerly known as Midatech Pharma plc) and its subsidiaries (the “Group”)
as of December 31, 2023 and 2022, and the related consolidated statements of comprehensive income, changes in equity, and cash flows